BS_H1ZS5FMZ
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 82.49014454664915
- age_years
- 9.499
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.658
- INTERFERON_GAMMA_RESPONSE+0.544
- E2F_TARGETS+0.497
- MYC_TARGETS_V2+0.482
- G2M_CHECKPOINT+0.470
- ALLOGRAFT_REJECTION+0.406
- NOTCH_SIGNALING+0.296
- MYC_TARGETS_V1+0.280
- INFLAMMATORY_RESPONSE+0.275
- IL6_JAK_STAT3_SIGNALING+0.249
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.331
- ANDROGEN_RESPONSE-0.253
- CHOLESTEROL_HOMEOSTASIS-0.253
- P53_PATHWAY-0.253
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.253
- HYPOXIA-0.227
- BILE_ACID_METABOLISM-0.226
- HEME_METABOLISM-0.196
- ADIPOGENESIS-0.193
- FATTY_ACID_METABOLISM-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03093 | — | cohortA1 | 0.877 |
| 2 | TCGA-22-5480-01A-01R-1635-07 | — | cohortSQ1 | 0.846 |
| 3 | 3F932445-1D8F-4128-A8DA-F36EA9F6E745 | — | — | 0.835 |
| 4 | TCGA-98-8023-01A-11R-2247-07 | — | cohortSQ1 | 0.834 |
| 5 | C3N-02152 | — | cohortA1 | 0.833 |
| 6 | TCGA-83-5908-01A-21R-2287-07 | — | cohortA1 | 0.832 |
| 7 | SRR934757 | — | — | 0.829 |
| 8 | 6DFB9EF2-4993-4CF1-B0F7-F8A9409DF3B5 | — | — | 0.816 |
| 9 | TCGA-S3-AA10-01A-21R-A41B-07 | — | E | 0.813 |
| 10 | BS_K17VQECG | high-grade glioma | — | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.658 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.544 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.497 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.482 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.406 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.296 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.275 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.249 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.208 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.201 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.201 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.173 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.161 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.136 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.112 | Inavolisib | — uncovered |
| COMPLEMENT | 0.107 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.103 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.079 | Inavolisib | — uncovered |